Michael Pehl has been appointed president and CEO of cancer drug developer Immunomedics (NASDAQ: IMMU). Pehl comes to the Morris Plains, NJ, company from Celgene (NASDAQ: CELG), where he was president, hematology & oncology. He will start his new position at Immunomedics on Dec. 7.
Immunomedics is moving forward with sacituzumab govitecan, a breast cancer drug in Phase 3 studies whose rights Seattle Genetics (NASDAQ: SGEN) agreed to acquire in February. But that deal unwound following challenges from Immunomedics shareholders, who took control of the company’s board of directors.